pharmaceuticals

Eli Lilly & Co. (NYSE:LLY) shares staged their sharpest single-day rally in nearly 25 years Thursday, after unveiling data from a pivotal trial that could cement its leadership in a weight-loss drug market projected to more than triple in size by 2030. The stock surged, closing the day up 14....

Last week, U.S. President Donald Trump disclosed plans for a “major tariff” on foreign pharmaceuticals. BofA Securities analyst said if the Trump administration plans to impose tariffs on the pharmaceutical industry, it would likely do so through a “Section 232...

A physician survey for Neurocrine Biosciences Inc's (NASDAQ:NBIX) Crenessity suggests "strong uptake across all patient segments," according to Needham.  The Neurocrine Biosciences Analyst: Analyst Ami Fadia upgraded the rating from Hold to Buy, while raising the price target to $138. The...

Abbott Laboratories (NYSE:ABT) will release its first-quarter earnings results before the opening bell on Wednesday, April 16. Analysts expect the company to report quarterly earnings at $1.07 per share, up from 98 cents per share in the year-ago period. According to data from Benzinga Pro, Abbott...

The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing. The agency aims to adopt human-relevant and technologically advanced testing methods to improve safety...

HC Wainwright initiated coverage on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), a commercial-stage biotech company focused on RNA-targeted therapeutics. Analyst Mitchell Kapoor says Ionis has used its RNA technology to develop a wide range of drugs. The analyst believes Ionis has built a strong and...

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is giving investors some good news — especially if they're keeping a close eye on its newly launched painkiller Journavx. Journavx Gains Early Traction At the 2025 Napa Valley Biotech Forum, JPMorgan analyst Jessica Fye walked away with a bullish tone after...

The U.S. Food and Drug Administration (FDA) on Thursday issued a Complete Response Letter for Aldeyra Therapeutics, Inc.’s (NASDAQ:ALDX) resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for dry eye disease. The FDA stated that the NDA...

Sunshine Biopharma Inc. (NASDAQ:SBFM) traded higher on Wednesday, with a session volume of 19.07 million compared to an average volume of 88.16K, according to data from Benzinga Pro. The company on Wednesday announced that it has completed additional studies on orthotopic human tumor models in mice...

Novo Holdings, the controlling shareholder of weight loss drugmaker Novo Nordisk A/S (NYSE:NVO), reported Wednesday income and investment returns of 60 billion Danish kroner (around $8.68 billion) for 2024. Novo Holdings owns 28.1% shares in Novo Nordisk. Dividends and the share repurchase programs...

Palatin Technologies Inc. (NYSE:PTN) on Friday released topline results from its Phase 2 study of PL8177, a selective melanocortin-1 receptor (MC1R) agonist, in patients with active ulcerative colitis. The Phase 2 randomized, placebo-controlled study evaluated 12 patients (nine in the PL8177...

Stifel initiated coverage on Monday on Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development...

Servier Laboratories and Black Diamond Therapeutics Inc. (NASDAQ:BDTX) on Wednesday announced a strategic worldwide licensing agreement for BDTX-4933 for solid tumors. Servier is a pharmaceutical company based in France governed by a non-profit foundation. Under the agreement, Servier will develop...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) shares traded higher on Monday after Health Canada approved its Zoryve cream for the treatment of mild to moderate atopic dermatitis. What To Know: This approval comes after data from phase 3 clinical trials showed that 90% of patients experienced symptom...

In January, the Food and Drug Administration (FDA) approved Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Journavx, a non-opioid oral pain signal inhibitor for acute pain. This marked the first approval of a new class of pain medication in more than 20 years, offering an alternative to traditional...